Chimerix

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 72

Market Cap: $88M

Website

Introduction: Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.

Clinical Trials

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Endometrial Cancer Recurrent

Interventions: Drug: ONC201

First Posted Date: 2018-04-02

Last Posted Date: 2022-11-09

Lead Sponsor: Chimerix

Target Recruit Count: 30

Registration Number: NCT03485729

Locations: 🇺🇸
Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

ONC201 in Pediatric H3 K27M Gliomas

Phase 1

Active, not recruiting

Conditions: Diffuse Intrinsic Pontine Glioma
Glioma, Malignant

Interventions: Drug: ONC201

First Posted Date: 2018-01-31

Last Posted Date: 2023-08-15

Lead Sponsor: Chimerix

Target Recruit Count: 130

Registration Number: NCT03416530

Locations: 🇺🇸
New York University, New York, New York, United States
🇺🇸
UCSF, Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States

and more 5 locations

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

Phase 2

Terminated

Conditions: Adenovirus

Interventions: Other: Standard of Care
Drug: Brincidofovir

First Posted Date: 2017-11-13

Last Posted Date: 2021-01-25

Lead Sponsor: Chimerix

Target Recruit Count: 29

Registration Number: NCT03339401

Locations: 🇺🇸
Joseph M. Sanzari Childrens Hospital-Regional Cancer Care, Hackensack, New Jersey, United States
🇵🇱
Uniwerstytecki Azpital Kliniczny we Wroclawiu, Wrocław, Dolnoslaskie, Poland
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 33 locations

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Phase 2

Active, not recruiting

Conditions: Glioma

Interventions: Drug: ONC201

First Posted Date: 2017-09-27

Last Posted Date: 2023-08-15

Lead Sponsor: Chimerix

Target Recruit Count: 95

Registration Number: NCT03295396

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Columbia University, New York, New York, United States

and more 6 locations

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Conditions: Glioma

First Posted Date: 2017-04-28

Last Posted Date: 2022-03-14

Lead Sponsor: Chimerix

Registration Number: NCT03134131

Locations: 🇺🇸
Oncoceutics, Philadelphia, Pennsylvania, United States

Dociparstat Sodium (CX-01) Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Idarubicin
Drug: Dociparstat sodium
Drug: Cytarabine

First Posted Date: 2016-08-19

Last Posted Date: 2023-09-07

Lead Sponsor: Chimerix

Target Recruit Count: 75

Registration Number: NCT02873338

Locations: 🇺🇸
Franciscan St. Francis Health, Indianapolis, Indiana, United States
🇺🇸
Baylor Research Institute/Baylor Sammons Cancer Center/Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States

and more 20 locations

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: ONC201
Drug: Dexamethasone

First Posted Date: 2016-08-11

Last Posted Date: 2024-07-03

Lead Sponsor: Chimerix

Target Recruit Count: 17

Registration Number: NCT02863991

Locations: 🇺🇸
The Mount Sinai Medical Center, New York, New York, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

Conditions: Adenovirus

First Posted Date: 2015-11-04

Last Posted Date: 2022-03-14

Lead Sponsor: Chimerix

Registration Number: NCT02596997

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Arkansas Medical Center, Little Rock, Arkansas, United States
🇺🇸
Methodist University Hospital-BMT program west clinic, Memphis, Tennessee, United States

and more 43 locations

Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma

Phase 2

Active, not recruiting

Conditions: H3 K27M Glioma
Thalamic Glioma
Basal Ganglia Glioma
Glioblastoma
Diffuse Midline Glioma
Infratentorial Glioma

Interventions: Drug: ONC201

First Posted Date: 2015-08-17

Last Posted Date: 2023-08-15

Lead Sponsor: Chimerix

Target Recruit Count: 89

Registration Number: NCT02525692

Locations: 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 2 locations

A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus

Phase 3

Terminated

Conditions: Cytomegalovirus Disease
Kidney Transplant Infection

Interventions: Drug: Valganciclovir
Drug: Brincidofovir

First Posted Date: 2015-05-12

Last Posted Date: 2021-07-16

Lead Sponsor: Chimerix

Target Recruit Count: 6

Registration Number: NCT02439957

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
University of Colorado Hospital/Health Science Center, Aurora, Colorado, United States
🇺🇸
St. Vincent Medical Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy